BioSante's CML vaccine gains orphan-drug status from FDA

06/7/2010 | International Business Times · Reuters

BioSante Pharmaceuticals said its experimental vaccine GVAX CML was granted orphan-drug designation by the FDA for treating patients with chronic myeloid leukemia. The drugmaker previously obtained orphan status for two other GVAX vaccines to treat pancreatic cancer and acute myeloid leukemia.

View Full Article in:

International Business Times · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA